Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling

Yue Wu; Yingqiu Zhang; Congcong Liu; Yang Zhang; Duchuang Wang; Shanshan Wang; Yueguang Wu; Fang Liu; Qiong Li; Xiuxiu Liu; Mohamed Y. Zaky; Dong Yan; Shuyan Liu

doi:10.1016/j.biopha.2019.108831

Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling

Yue Wu, Yingqiu Zhang, Congcong Liu, Yang Zhang, Duchuang Wang, Shanshan Wang, Yueguang Wu, Fang Liu, Qiong Li, Xiuxiu Liu, Mohamed Y. Zaky, Dong Yan, Shuyan Liu^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

USP13 is emerging as a potential target in cancer therapy. However, the effect of USP13 on tumor progression is controversial. Here we focused on non-small cell lung cancer (NSCLC), a common cancer with high mortality, and studied the role of USP13 in tumor growth. By analysis of multi-level genetic database, we found USP13 is high expressed in heart among healthy primary tissues and is most amplified in lung cancer. Clinical samples of NSCLC showed tumor exhibited high USP13 level compared with adjacent normal tissues. We further utilized lung adenocarcinoma A549 and squamous carcinoma H226 cells as cell model and investigated USP13 effect by USP13 knockdown. As a results, downregulation of USP13 dramatically inhibited A549 and H226 cell proliferation by AKT/MAPK signaling and suppressed tumor growth in nude mice. Collectively, we identified USP13 as a tumor promoter in NSCLC and provide a promising target in cancer therapy.

Original language	English
Article number	108831
Journal	Biomedicine and Pharmacotherapy
Volume	114
DOIs	https://doi.org/10.1016/j.biopha.2019.108831
Publication status	Published - Jun 2019
Externally published	Yes

Keywords

AKT/MAPK signaling
Amplification
NSCLC
Tumor promoter
USP13

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biopha.2019.108831

Cite this

@article{ded80c1a8c894764a8b6a9e214fd112e,

title = "Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling",

abstract = "USP13 is emerging as a potential target in cancer therapy. However, the effect of USP13 on tumor progression is controversial. Here we focused on non-small cell lung cancer (NSCLC), a common cancer with high mortality, and studied the role of USP13 in tumor growth. By analysis of multi-level genetic database, we found USP13 is high expressed in heart among healthy primary tissues and is most amplified in lung cancer. Clinical samples of NSCLC showed tumor exhibited high USP13 level compared with adjacent normal tissues. We further utilized lung adenocarcinoma A549 and squamous carcinoma H226 cells as cell model and investigated USP13 effect by USP13 knockdown. As a results, downregulation of USP13 dramatically inhibited A549 and H226 cell proliferation by AKT/MAPK signaling and suppressed tumor growth in nude mice. Collectively, we identified USP13 as a tumor promoter in NSCLC and provide a promising target in cancer therapy.",

keywords = "AKT/MAPK signaling, Amplification, NSCLC, Tumor promoter, USP13",

author = "Yue Wu and Yingqiu Zhang and Congcong Liu and Yang Zhang and Duchuang Wang and Shanshan Wang and Yueguang Wu and Fang Liu and Qiong Li and Xiuxiu Liu and Zaky, {Mohamed Y.} and Dong Yan and Shuyan Liu",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = jun,

doi = "10.1016/j.biopha.2019.108831",

language = "English",

volume = "114",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson s.r.l.",

}

TY - JOUR

T1 - Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling

AU - Wu, Yue

AU - Zhang, Yingqiu

AU - Liu, Congcong

AU - Zhang, Yang

AU - Wang, Duchuang

AU - Wang, Shanshan

AU - Wu, Yueguang

AU - Liu, Fang

AU - Li, Qiong

AU - Liu, Xiuxiu

AU - Zaky, Mohamed Y.

AU - Yan, Dong

AU - Liu, Shuyan

PY - 2019/6

Y1 - 2019/6

N2 - USP13 is emerging as a potential target in cancer therapy. However, the effect of USP13 on tumor progression is controversial. Here we focused on non-small cell lung cancer (NSCLC), a common cancer with high mortality, and studied the role of USP13 in tumor growth. By analysis of multi-level genetic database, we found USP13 is high expressed in heart among healthy primary tissues and is most amplified in lung cancer. Clinical samples of NSCLC showed tumor exhibited high USP13 level compared with adjacent normal tissues. We further utilized lung adenocarcinoma A549 and squamous carcinoma H226 cells as cell model and investigated USP13 effect by USP13 knockdown. As a results, downregulation of USP13 dramatically inhibited A549 and H226 cell proliferation by AKT/MAPK signaling and suppressed tumor growth in nude mice. Collectively, we identified USP13 as a tumor promoter in NSCLC and provide a promising target in cancer therapy.

AB - USP13 is emerging as a potential target in cancer therapy. However, the effect of USP13 on tumor progression is controversial. Here we focused on non-small cell lung cancer (NSCLC), a common cancer with high mortality, and studied the role of USP13 in tumor growth. By analysis of multi-level genetic database, we found USP13 is high expressed in heart among healthy primary tissues and is most amplified in lung cancer. Clinical samples of NSCLC showed tumor exhibited high USP13 level compared with adjacent normal tissues. We further utilized lung adenocarcinoma A549 and squamous carcinoma H226 cells as cell model and investigated USP13 effect by USP13 knockdown. As a results, downregulation of USP13 dramatically inhibited A549 and H226 cell proliferation by AKT/MAPK signaling and suppressed tumor growth in nude mice. Collectively, we identified USP13 as a tumor promoter in NSCLC and provide a promising target in cancer therapy.

KW - AKT/MAPK signaling

KW - Amplification

KW - NSCLC

KW - Tumor promoter

KW - USP13

UR - http://www.scopus.com/inward/record.url?scp=85064069809&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2019.108831

DO - 10.1016/j.biopha.2019.108831

M3 - Article

C2 - 30986623

AN - SCOPUS:85064069809

SN - 0753-3322

VL - 114

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

M1 - 108831

ER -

Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this